Eroom's law: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
 
Line 1: Line 1:
Eroom's law is the observation that drug discovery is becoming slower and more expensive over time, despite improvements in technology (such as high-throughput screening, biotechnology, combinatorial chemistry, and computational drug design), a trend first observed in the 1980s. The cost of developing a new drug roughly doubles every nine years (inflation-adjusted). In order to highlight the contrast with the exponential advancements of other forms of technology (such as transistors) over time, the law was deliberately spelled as Moore's law spelled backwards<br>[[Category:Drugs]]<br>
'''Eroom's law''' is the observation that [[drug discovery]] is becoming slower and more expensive over time, despite improvements in [[technology]], such as [[high-throughput screening]], [[biotechnology]], [[combinatorial chemistry]], and [[computational drug design]]. This trend was first observed in the 1980s. The cost of developing a new [[pharmaceutical drug]] roughly doubles every nine years (inflation-adjusted).
{{stb}}
 
{{dictionary-stub2}}
The name '''Eroom's law''' is a deliberate reversal of [[Moore's law]], which describes the exponential advancement of [[transistor]] technology over time. By contrast, Eroom's law highlights the stagnation and increasing costs in [[pharmaceutical research and development]] (R&D).
{{short-articles-ni}}
 
{{No image}}
== Observations and Implications ==
Eroom's law suggests that, despite advances in '''medical science and technology''', the process of discovering and bringing new drugs to market has become '''less efficient''' over time. The trend has significant implications for:
* '''Pharmaceutical industry profitability''' – Increasing costs put pressure on [[pharmaceutical companies]].
* '''Drug pricing''' – Higher R&D costs contribute to expensive prescription medications.
* '''Innovation in drug development''' – Companies must find new strategies to improve efficiency.
 
== Contributing Factors ==
Several factors contribute to the increasing costs and inefficiency in '''drug discovery''':
* '''Regulatory burden''' – Stricter [[clinical trial]] requirements increase development time.
* '''Efficacy challenges''' – Many new drug candidates fail due to '''lack of effectiveness'''.
* '''Rising complexity''' – Modern drugs often target complex '''biological pathways''', requiring more extensive research.
* '''"Better than the Beatles" problem''' – New drugs must outperform existing, well-established treatments.
* '''Economic pressures''' – The high cost of failure in '''late-stage drug trials''' adds to the overall expenses.
 
== Contrasts with Moore's Law ==
* '''[[Moore's law]]''' predicts that the number of transistors on an integrated circuit doubles approximately every two years, leading to rapid technological advancements.
* '''Eroom's law''', by contrast, describes an '''inverse''' trend in '''drug development''', where costs and time '''increase''' instead of decrease.
 
== Strategies to Address Eroom's Law ==
Efforts to counteract the trend of Eroom's law include:
* '''AI-driven drug discovery''' – Using '''artificial intelligence''' and '''machine learning''' to accelerate '''target identification''' and '''drug screening'''.
* '''Adaptive clinical trials''' – Designing more '''flexible''' and '''efficient''' trial methodologies.
* '''Collaboration between industry and academia''' – Improving knowledge sharing and reducing redundancy in '''biomedical research'''.
* '''Regulatory reforms''' – Streamlining approval processes without compromising safety.
* '''Precision medicine''' – Developing more '''targeted therapies''' to increase success rates.
 
== Related Pages ==
* [[Drug discovery]]
* [[Pharmaceutical industry]]
* [[Clinical trials]]
* [[Moore's law]]
* [[Biomedical research]]
* [[Artificial intelligence in drug discovery]]
* [[Pharmaceutical pricing]]
 
== See Also ==
* [[Biomedical innovation]]
* [[Translational medicine]]
* [[Computational drug design]]
* [[High-throughput screening]]
 
[[Category:Pharmaceutical industry]]
[[Category:Drug discovery]]
[[Category:Medical research]]
[[Category:Health economics]]
[[Category:Biomedical innovation]]

Latest revision as of 14:34, 10 March 2025

Eroom's law is the observation that drug discovery is becoming slower and more expensive over time, despite improvements in technology, such as high-throughput screening, biotechnology, combinatorial chemistry, and computational drug design. This trend was first observed in the 1980s. The cost of developing a new pharmaceutical drug roughly doubles every nine years (inflation-adjusted).

The name Eroom's law is a deliberate reversal of Moore's law, which describes the exponential advancement of transistor technology over time. By contrast, Eroom's law highlights the stagnation and increasing costs in pharmaceutical research and development (R&D).

Observations and Implications[edit]

Eroom's law suggests that, despite advances in medical science and technology, the process of discovering and bringing new drugs to market has become less efficient over time. The trend has significant implications for:

  • Pharmaceutical industry profitability – Increasing costs put pressure on pharmaceutical companies.
  • Drug pricing – Higher R&D costs contribute to expensive prescription medications.
  • Innovation in drug development – Companies must find new strategies to improve efficiency.

Contributing Factors[edit]

Several factors contribute to the increasing costs and inefficiency in drug discovery:

  • Regulatory burden – Stricter clinical trial requirements increase development time.
  • Efficacy challenges – Many new drug candidates fail due to lack of effectiveness.
  • Rising complexity – Modern drugs often target complex biological pathways, requiring more extensive research.
  • "Better than the Beatles" problem – New drugs must outperform existing, well-established treatments.
  • Economic pressures – The high cost of failure in late-stage drug trials adds to the overall expenses.

Contrasts with Moore's Law[edit]

  • Moore's law predicts that the number of transistors on an integrated circuit doubles approximately every two years, leading to rapid technological advancements.
  • Eroom's law, by contrast, describes an inverse trend in drug development, where costs and time increase instead of decrease.

Strategies to Address Eroom's Law[edit]

Efforts to counteract the trend of Eroom's law include:

  • AI-driven drug discovery – Using artificial intelligence and machine learning to accelerate target identification and drug screening.
  • Adaptive clinical trials – Designing more flexible and efficient trial methodologies.
  • Collaboration between industry and academia – Improving knowledge sharing and reducing redundancy in biomedical research.
  • Regulatory reforms – Streamlining approval processes without compromising safety.
  • Precision medicine – Developing more targeted therapies to increase success rates.

Related Pages[edit]

See Also[edit]